Nigeria approves emergency use of China's Sinopharm COVID-19 vaccine
LAGOS, Aug. 24 (Xinhua) -- Nigerian authorities have approved the emergency use of the Sinopharm COVID-19 vaccine amid efforts to battle the third wave of infections in the country, an official said on Tuesday.
Faisal Shuaib, head of the National Primary Health Care Development Agency, said the National Agency for Food, Drug Administration and Control (NAFDAC) has certified the Chinese vaccine for emergency use after carrying out the final assessment of the vaccine.
"NAFDAC has approved Sinopharm vaccine, the approval was done three days ago; and yes, Sinopharm vaccine has also received WHO certification," Shuaib told a press conference in Abuja on Tuesday.
"So, it is a potential vaccine that we could use," he added.
Last week, the West African country started the second phase of its COVID-19 vaccination program.
It has been grappling with rising confirmed cases since late June, with an ambitious goal of vaccinating at least 40 percent of its population by the end of this year, and 70 percent by the end of 2022.
Nigeria reported 565 new COVID-19 cases on Monday, bringing the total caseload to 187,588, while a total of 2,276 people have died from the virus, according to the Nigeria Center for Disease Control.
Photos
- Dance show saluting traditional culture of the Song Dynasty makes its debut
- Village in SW China’s Yunnan embraces prosperity through agricultural tourism
- Eighth birthday for pair of giant pandas celebrated in Haikou, Hainan province
- Olympic gold medalists portrayed in Shanxi artist’s polymer clay sculptures
Related Stories
- Chinese hospitals asked to keep adequate epidemic control staff
- Commentary: People's active participation helps contain COVID-19 epidemic in China
- Chinese Embassy in Britain condemns Channel 4's documentary on COVID-19 origins tracing
- Chinese envoy urges WHO to uphold science-based origins-tracing
- Chinese embassy donates oxygen concentrators to help Myanmar fight COVID-19
Copyright © 2021 People's Daily Online. All Rights Reserved.